Topicort label

Topicort

Topicort Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Topicort® (desoximetasone) Ointment 0.25% is not for ophthalmic use.

Keep out of reach of children.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Topicort® (desoximetasone) Ointment 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

History

There is currently no drug history available for this drug.

Other Information

Topicort® (desoximetasone) Ointment 0.25% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.

Each gram of Topicort® Ointment 0.25% contains 2.5 mg of desoximetasone in an ointment base consisting of white petrolatum and fractionated coconut oil.

The chemical name of desoximetasone is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-,(11β,16α)-.

Desoximetasone has the molecular formula C22H29FO4 and a molecular weight of 376.47. The CAS Registry Number is 382-67-2.

The structural formula is:

Chemical Structure

Topicort Manufacturers

  • Taro Pharmaceuticals U.s.a., Inc.
    Topicort | Taro Pharmaceuticals U.s.a., Inc.
    No Recall

    Topicort | Taro Pharmaceuticals U.s.a., Inc.

    Topicort | Taro Pharmaceuticals U.s.a., Inc.

    Apply a thin film of Topicort® (desoximetasone) Ointment 0.25% to the affected skin areas twice daily. Rub in gently.

  • Taro Pharmaceuticals U.s.a., Inc.
    Topicort | Taro Pharmaceuticals U.s.a., Inc.
    No Recall

    Topicort | Taro Pharmaceuticals U.s.a., Inc.

    Topicort | Taro Pharmaceuticals U.s.a., Inc.

    Apply a thin film of Topicort® (desoximetasone cream USP) 0.05%, Topicort® (desoximetasone cream USP) 0.25%, or Topicort® (desoximetasone gel USP) 0.05% to the affected skin areas twice daily. Rub in gently.

  • Taro Pharmaceuticals U.s.a., Inc.
    Topicort | Roerig
    No Recall

    Topicort | Roerig

    Topicort | Roerig

    Buffered Penicillin G Potassium for Injection, USP may be given intravenously or intramuscularly. The usual dose recommendations are as follows:

    Adult patients CLINICAL INDICATION DOSAGE * Because of its short half-life, Penicillin G is administered in divided doses, usually every 4–6 hours with the exception of meningococcal meningitis/septicemia, i.e., every 2 hours. Serious infections due to susceptible strains of streptococci (including S. pneumoniae) 12 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4–6 hours. -septicemia, empyema, pneumonia, pericarditis, endocarditis and meningitis Serious infections due to susceptible strains of staphylococci 5 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4–6 hours. -septicemia, empyema, pneumonia, pericarditis, endocarditis and meningitis Anthrax Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism. Actinomycosis   Cervicofacial disease 1 to 6 million units/day(*)   Thoracic and abdominal disease 10 to 20 million units/day(*) Clostridial infections   Botulism (adjunctive therapy to antitoxin) 20 million units/day(*)   Gas gangrene (debridement and/or surgery as indicated)   Tetanus (adjunctive therapy to human tetanus immune globulin) Diphtheria (adjunctive therapy to antitoxin and for the prevention of the carrier state) 2 to 3 million units/day in divided doses for 10–12 days(*) Erysipelothrix endocarditis 12 to 20 million units/day for 4–6 weeks(*) Fusospirochetosis (severe infections of the oropharynx [Vincent's], lower respiratory tract and genital area) 5 to 10 million units/day(*) Listeria infections   Meningitis 15 to 20 million units/day for 2 weeks(*)   Endocarditis 15 to 20 million units/day for 4 weeks(*) Pasteurella infections including bacteremia and meningitis 4 to 6 million units/day for 2 weeks(*) Haverhill fever; Rat-bite fever 12 to 20 million units/day for 3–4 weeks(*) Disseminated gonococcal infections, such as meningitis, endocarditis, arthritis, etc., caused by penicillin – susceptible organisms 10 million units/day(*); duration depends on the type of infection Syphilis (neurosyphilis) 12 to 24 million units/day, as 2–4 MU every 4 hours for 10–14 days; many experts recommend additional therapy with Benzathine PCN G 2.4 MU IM weekly for 3 doses after completion of IV therapy Meningococcal meningitis and/or septicemia 24 million units/day as 2 million units every 2 hours Pediatric patients

    This product should not be administered to patients requiring less than one million units per dose (see Precautions-Pediatric Use).

    CLINICAL INDICATION DOSAGE Serious infections, such as pneumonia and endocarditis, due to susceptible strains of streptococci (including S. pneumoniae) and meningococcus 150,000–300,000 units/kg/day divided in equal doses every 4–6 hours; duration depends on infecting organism and type of infection Meningitis caused by susceptible strains of pneumococcus and meningococcus 250,000 units/kg/day divided in equal doses every 4 hours for 7–14 days depending on the infecting organism (maximum dose of 12–20 million units/day) Disseminated Gonococcal Infections (penicillin-susceptible strains) Weight less than 45 kg: Arthritis 100,000 units/kg/day in 4 equally divided doses for 7–10 days Meningitis 250,000 units/kg/day in equal doses every 4 hours for 10–14 days Endocarditis 250,000 units/kg/day in equal doses every 4 hours for 4 weeks Arthritis, meningitis, endocarditis Weight 45 kg or greater: 10 million units/day in equally divided doses with the duration of therapy depending on the type of infection Syphilis (congenital and neurosyphilis) after the newborn period 200,000–300,000 units/kg/day (administered as 50,000 units/kg every 4–6 hours) for 10–14 days Diphtheria (adjunctive therapy to antitoxin and for prevention of the carrier state) 150,000–250,000 units/kg/day in equal doses every 6 hours for 7–10 days Rat-bite fever; Haverhill fever (with endocarditis caused by S. moniliformis) 150,000–250,000 units/kg/day in equal doses every 4 hours for 4 weeks Renal Impairment

    Penicillin G is relatively nontoxic, and dosage adjustments are generally required only in cases of severe renal impairment. The recommended dosage regimens are as follows:

    Creatinine clearance less than 10 mL/min/1.73m2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 8–10 hours.

    Uremic patients with a creatinine clearance greater than 10 mL/min/1.73m2; administer a full loading dose (see recommended dosages in the tables above) followed by one-half of the loading dose every 4–5 hours. Additional dosage modification should be made in patients with hepatic disease and renal impairment.

    For most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asymptomatic. Antibiotic therapy for Group A β-hemolytic streptococcal infections should be maintained for atleast 10 days to reduce the risk of rheumatic fever.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

    Reconstitution

    The following table shows the amount of solvent required for solution of various concentrations:

    Approx. Desired Concentration
    (units/mL) Approx. Volume (mL)
    1,000,000
    units Solvent for Vial of 5,000,000
    units Infusion Only 20,000,000
    units 50,000 20.0 – – 100,000 10.0 – – 250,000 4.0 18.2 75.0 500,000 1.8 8.2 33.0 750,000 – 4.8 – 1,000,000 – 3.2 11.5

    When the required volume of solvent is greater than the capacity of the vial, the penicillin can be dissolved by first injecting only a portion of the solvent into the vial, then withdrawing the resultant solution and combining it with the remainder of the solvent in a larger sterile container.

    Buffered Pfizerpen (penicillin G potassium) for Injection is highly water soluble. It may be dissolved in small amounts of Water for Injection, or Sterile Isotonic Sodium Chloride Solution for Parenteral Use. All solutions should be stored in a refrigerator. When refrigerated, penicillin solutions may be stored for seven days without significant loss of potency.

    Buffered Pfizerpen for Injection may be given intramuscularly or by continuous intravenous drip for dosages of 500,000, 1,000,000, or 5,000,000 units. It is also suitable for intrapleural, intraarticular, and other local instillations.

    THE 20,000,000 UNIT DOSAGE MAY BE ADMINISTERED BY INTRAVENOUS INFUSION ONLY.

    (1) Intramuscular Injection

    Keep total volume of injection small. The intramuscular route is the preferred route of administration. Solutions containing up to 100,000 units of penicillin per mL of diluent may be used with a minimum of discomfort. Greater concentration of penicillin G per mL is physically possible and may be employed where therapy demands. When large dosages are required, it may be advisable to administer aqueous solutions of penicillin by means of continuous intravenous drip.

    (2) Continuous Intravenous Drip

    Determine the volume of fluid and rate of its administration required by the patient in a 24 hour period in the usual manner for fluid therapy, and add the appropriate daily dosage of penicillin to this fluid. For example, if an adult patient requires 2 liters of fluid in 24 hours and a daily dosage of 10 million units of penicillin, add 5 million units to 1 liter and adjust the rate of flow so the liter will be infused in 12 hours.

    (3) Intrapleural or Other Local Infusion

    If fluid is aspirated, give infusion in a volume equal to ¼ or ½ the amount of fluid aspirated, otherwise, prepare as for intramuscular injection.

    (4) Intrathecal Use

    The intrathecal use of penicillin in meningitis must be highly individualized. It should be employed only with full consideration of the possible irritating effects of penicillin when used by this route. The preferred route of therapy in bacterial meningitides is intravenous, supplemented by intramuscular injection.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    Sterile solution may be left in refrigerator for one week without significant loss of potency.

  • Taro Pharmaceuticals U.s.a., Inc.
    Topicort | Penleigh Irving Ltd
    No Recall

    Topicort | Penleigh Irving Ltd

    Topicort | Penleigh Irving Ltd

    There is currently no dosage information available for this product. We apologize for any inconvenience.